Azzad Asset Management Inc. ADV Invests $161,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Azzad Asset Management Inc. ADV acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,192 shares of the company’s stock, valued at approximately $161,000.

Other large investors also recently modified their holdings of the company. Mubadala Investment Co PJSC acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $128,041,000. Citigroup Inc. raised its holdings in shares of Recursion Pharmaceuticals by 165.3% in the 3rd quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock valued at $3,599,000 after purchasing an additional 293,174 shares during the period. Gladstone Institutional Advisory LLC bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $133,000. Norges Bank bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $34,825,000. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Recursion Pharmaceuticals by 161.2% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after purchasing an additional 5,680,656 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $3,860,644.97. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total transaction of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $3,860,644.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the transaction, the chief executive officer now directly owns 863,524 shares in the company, valued at $6,675,040.52. The disclosure for this sale can be found here. Insiders have sold a total of 207,359 shares of company stock valued at $1,704,435 in the last three months. 15.75% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Recursion Pharmaceuticals Stock Up 2.7 %

Recursion Pharmaceuticals stock opened at $7.35 on Thursday. The stock has a market cap of $1.75 billion, a P/E ratio of -4.59 and a beta of 0.83. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $16.75. The company’s 50-day moving average price is $8.82 and its two-hundred day moving average price is $9.90.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.04. The firm had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The business’s revenue was up 14.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.34) EPS. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.